Epidemiology Insights and Forecast
Disease Burden insights, powered with real-world data
Thelansis provides robust epidemiology insights built on validated methodologies, real-world registries, healthcare utilization data, clinical literature, and expert review. Our Epidemiology Insights deliver a comprehensive understanding of disease burden, by prevalence, incidence, diagnosed cases, comorbidities, clinical manifestations and severity stratification across geographies. This help quantify the true patient population, disease progression, and forecast trends across major global markets.
What We Provide:
- 8 MM/20+ Country Epidemiology Forecasts
- Prevalence, Incidence, Mortality & Survival Estimates
- Population Segmentation by Stage, Biomarker, Severity & Line of Therapy
- Prognostic Subgroup Analysis for targeted therapies
- Population Flow Models (undiagnosed → diagnosed → treated → eligible)
- Methodology Based on Published Literature, Registries & Expert Validation
How It Helps You:
Accurate epidemiology is essential for:
- Opportunity assessment and market sizing
- Clinical development planning
- Reimbursement dossiers
- Commercial strategy and resource allocation
- Health technology assessments (HTA)
What Strategic Answers Clients Will Receive:
- How large is the patient population today (incidence, prevalence, segments)?
- How will the epidemiology evolve over time, and what factors will drive those changes?
- What are the key patient subgroups by stage, biomarker, severity, and treatment status?
- How does patient progression flow across the disease continuum?
- What is the realistic addressable patient pool for current and future therapies?
- How do epidemiology trends differ across the US, EU5, Japan, China, and other 20+ emerging markets?
Reports:
Market Access and Reimbursement Insights
Thelansis’s “Dyslipidemia Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Emerging Therapy, Unmet Needs and TPP Insights
Thelansis’s “Dyslipidemia Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Epidemiology Insights and Forecast
Thelansis’s “Global Dyslipidemia Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets.
Epidemiology Insights and Forecast
Thelansis’s “Dyslipidemia Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Market Outlook and Forecast
Thelansis’s “Global Dyslipidemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dyslipidemia treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Market Outlook and Forecast
Thelansis’s “Dyslipidemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dyslipidemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.

